Neurochemical Research Corp., a marketer of Condition-specific dietary supplements company Neurochemical Research Corp., this week revealed new evidence to support its latest product for the eyes. Recently validated by a National Eye Institute (NEI) Study, the company's product VisionKare(TM), was developed for macular degeneration sufferers. The company claims that the study found that high levels of antioxidants and zinc found in the VisionKare product significantly reduce the risk of advanced age-related macular degeneration (AMD) and its associated vision loss. Company president Carol Slavin said, "Neurochemical Research decreased the dosage of nutrients utilised in the study because older people who suffer from this disorder take a considerable number of medications and high-dose nutrients can interfere with their other medications." She boldly added: "We formulated a similar, but more complex product utilising the recommended antioxidants and zinc plus other highly specific eye nutrients which will help preserve the sight of the more than 13 million people over the age of 65 who have macular degeneration." Paul A. Sieving, M.D., Ph.D, director of National Eye Institute said, "This is an exciting discovery because, for people at high risk for developing advanced AMD, these nutrients are the first effective treatment to slow the progression of the disease."